Efficacy of autologous whole blood or serum therapy for chronic spontaneous urticaria: a systematic review and meta-analysis

2019 ◽  
Vol 30 (8) ◽  
pp. 818-825
Author(s):  
Hua-Ching Chang ◽  
Chih-Wei Sung ◽  
Ming-Hsiu Lin
2018 ◽  
Vol 6 (2) ◽  
pp. 586-599 ◽  
Author(s):  
Kanokvalai Kulthanan ◽  
Pichanee Chaweekulrat ◽  
Chulaluk Komoltri ◽  
Saowalak Hunnangkul ◽  
Papapit Tuchinda ◽  
...  

2020 ◽  
Vol 1 (4) ◽  
pp. 633-641 ◽  
Author(s):  
Ellen Crowe ◽  
Stacia M. DeSantis ◽  
Austin Bonnette ◽  
Jan O. Jansen ◽  
Jose‐Miguel Yamal ◽  
...  

Author(s):  
Nikolaos Aggelis Kitsioulis ◽  
Efterpi Zafiriou ◽  
Paraskevi Xepapadaki ◽  
Styliani Taka ◽  
Nikolaos G. Papadopoulos ◽  
...  

There is no Abstract.


2017 ◽  
Vol 172 (3) ◽  
pp. 161-166 ◽  
Author(s):  
Nikolaos Aggelis Kitsioulis ◽  
Paraskevi Xepapadaki ◽  
Aggeliki-Victoria Roussaki-Schulze ◽  
Nikolaos Papadopoulos ◽  
Efterpi Zafiriou

BMJ Open ◽  
2021 ◽  
Vol 11 (10) ◽  
pp. e043967
Author(s):  
Anna E Ssentongo ◽  
Paddy Ssentongo ◽  
Emily Heilbrunn ◽  
Lacee Laufenberg Puopolo ◽  
Vernon M Chinchilli ◽  
...  

IntroductionThere is a renewed interest in the use of whole blood (WB) to manage patients with life-threatening bleeding. We aimed to estimate mortality and complications risk between WB and blood component therapy for haemostatic resuscitation of major bleeding.MethodsWe will conduct a systematic review and meta-analysis of studies published between 1 January 1980 and 1 January 2020, identified from PubMed and Scopus databases. Population will be patients who require blood transfusion (traumatic operative, obstetric and gastrointestinal bleeding). Intervention is WB transfusion such as fresh WB (WB unit stored for less than 48 hours), leukoreduced modified WB (with platelets removed during filtration), warm fresh WB (stored warm at 22°C for up to 8 hours and then for a maximum of an additional 24 hours at 4°C). The primary outcomes will be the 24-hour and 30-day survival rates (in-hospital mortality). Comparator is blood component therapy (red blood cells, fresh-frozen plasma and platelets given together in a 1:1:1 unit ratio). The Cochrane risk of bias tool for randomised controlled trials and Risk Of Bias In Non-randomised Studies - of Interventions (ROBINS-I) for observation studies will be used to assess the risk of bias of included studies. We will use random-effects models for the pooling of studies. Interstudy heterogeneity will be assessed by the Cochran Q statistic, where p<0.10 will be considered statistically significant and quantified by I2 statistic, where I2 ≥50% will indicate substantial heterogeneity. We will perform subgroup and meta-regression analyses to assess geographical differences and other study-level factors explaining variations in the reported mortality risk. Results will be reported as risk ratios and their 95% CIs.Ethics and disseminationNo ethics clearance is required as no primary data will be collected. The results will be presented at scientific conferences and published in a peer-reviewed journal.


Sign in / Sign up

Export Citation Format

Share Document